{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:45:04Z","timestamp":1791402304922,"version":"4.3.3"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.leukres.2025.108144","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T16:01:16Z","timestamp":1764345676000},"page":"108144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia"],"prefix":"10.1016","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7552-7980","authenticated-orcid":false,"given":"Cameron J.","family":"Hunter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-6959","authenticated-orcid":false,"given":"Andrew","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3392-4909","authenticated-orcid":false,"given":"Heidi","family":"Roeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Eighmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan Philipp","family":"Bewersdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai A.","family":"Podoltsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8542-2944","authenticated-orcid":false,"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2025.108144_bib1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/hematology.2020000098","article-title":"Updates in infection risk and management in acute leukemia","volume":"2020","author":"Logan","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"1","key":"10.1016\/j.leukres.2025.108144_bib2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/mmy\/myw114","article-title":"Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality?","volume":"55","author":"Dragonetti","year":"2017","journal-title":"Med Mycol."},{"issue":"3","key":"10.1016\/j.leukres.2025.108144_bib3","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V90.3.999","article-title":"Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management","volume":"90","author":"Boutati","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2025.108144_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: systematic review of the literature","volume":"32","author":"Lin","year":"2001","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.leukres.2025.108144_bib5","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.leukres.2025.108144_bib6","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1086\/514731","article-title":"Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)","volume":"28","author":"Viscoli","year":"1999","journal-title":"Clin. Infect. Dis."},{"issue":"26","key":"10.1016\/j.leukres.2025.108144_bib7","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/blood-2015-07-627323","article-title":"Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia","volume":"126","author":"Halpern","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2025.108144_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.6004\/jnccn.2024.0056","article-title":"Prevention and Treatment of Cancer-Related Infections, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Baden","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"7","key":"10.1016\/j.leukres.2025.108144_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41375-025-02586-7","article-title":"Ecil, Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)","volume":"39","author":"Pagano","year":"2025","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2025.108144_bib10","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/jac\/dkad143","article-title":"Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"78","author":"Stemler","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.leukres.2025.108144_bib11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.leukres.2025.108144_bib12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2011.051995","article-title":"Comparative clinical effectiveness of prophylactic voriconazole\/posaconazole to fluconazole\/itraconazole in patients with acute myeloid leukemia\/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period","volume":"97","author":"Ananda-Rajah","year":"2012","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.leukres.2025.108144_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00355-18","article-title":"Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials","volume":"62","author":"Lee","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.leukres.2025.108144_bib14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","article-title":"Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation","volume":"155","author":"Marks","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2025.108144_bib15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00277-013-1693-5","article-title":"Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis","volume":"92","author":"Ping","year":"2013","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2025.108144_bib16","article-title":"Adverse Effects Associated With Currently Commonly Used Antifungal Agents: A Network Meta-Analysis and Systematic Review","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharm."},{"issue":"3","key":"10.1016\/j.leukres.2025.108144_bib17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ijantimicag.2017.03.021","article-title":"Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies","volume":"50","author":"Hachem","year":"2017","journal-title":"Int J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.leukres.2025.108144_bib18","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2352-3026(21)00232-5","article-title":"Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs","volume":"9","author":"Bruggemann","year":"2022","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2025.108144_bib19","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/S2352-3026(22)00073-4","article-title":"Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association","volume":"9","author":"Stemler","year":"2022","journal-title":"Lancet Haematol."},{"issue":"7","key":"10.1016\/j.leukres.2025.108144_bib20","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00277-020-04107-1","article-title":"Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma","volume":"99","author":"Stemler","year":"2020","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2025.108144_bib21","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1111\/bcp.15743","article-title":"Clinically relevant bidirectional drug-drug interaction between midostaurin and voriconazole","volume":"89","author":"Haefliger","year":"2023","journal-title":"Br. J. Clin. Pharm."},{"issue":"11","key":"10.1016\/j.leukres.2025.108144_bib22","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/cncr.35251","article-title":"Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"130","author":"Dinh","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2025.108144_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27613","article-title":"Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals","author":"Kawedia","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"10020","key":"10.1016\/j.leukres.2025.108144_bib24","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.leukres.2025.108144_bib25","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"FungiScope Mucormycosis, Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect. Dis."},{"issue":"9","key":"10.1016\/j.leukres.2025.108144_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00177-22","article-title":"New Perspectives on Antimicrobial Agents: Isavuconazole","volume":"66","author":"Lewis","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.leukres.2025.108144_bib27","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2147\/TCRM.S90335","article-title":"Role of isavuconazole in the treatment of invasive fungal infections","volume":"12","author":"Wilson","year":"2016","journal-title":"Ther. Clin. Risk Manag"},{"issue":"1","key":"10.1016\/j.leukres.2025.108144_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/cid\/ciae203","article-title":"Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review","volume":"79","author":"Boutin","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.leukres.2025.108144_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf163","article-title":"Incidence of Breakthrough Fungal Infections in Patients with Isavuconazole Prophylaxis: A Systematic Review and Meta-Analysis","author":"Ishida","year":"2025","journal-title":"Open Forum Infect. Dis."},{"issue":"12","key":"10.1016\/j.leukres.2025.108144_bib30","first-page":"3221","article-title":"L. the European, European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"issue":"30","key":"10.1016\/j.leukres.2025.108144_bib31","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2025.108144_bib32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N. Engl. J. Med"},{"issue":"11","key":"10.1016\/j.leukres.2025.108144_bib33","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/cncr.20688","article-title":"CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer","volume":"101","author":"Borg","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2025.108144_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/myc.12101","article-title":"Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis","volume":"57","author":"Lewis","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.leukres.2025.108144_bib35","author":"Li","year":"2025","journal-title":"StatPearls Treasure Isl. (FL)"},{"issue":"3","key":"10.1016\/j.leukres.2025.108144_bib36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.amjmed.2015.10.029","article-title":"Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status","volume":"129","author":"Lo Re","year":"2016","journal-title":"Am. J. Med"},{"issue":"12","key":"10.1016\/j.leukres.2025.108144_bib37","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2025.108144_bib38","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.leukres.2025.108144_bib39","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"M. the European Confederation of Medical, Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"issue":"7","key":"10.1016\/j.leukres.2025.108144_bib40","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1469-0691.2009.02990.x","article-title":"Voriconazole concentrations and outcome of invasive fungal infections","volume":"16","author":"Miyakis","year":"2010","journal-title":"Clin. Microbiol Infect."},{"issue":"12","key":"10.1016\/j.leukres.2025.108144_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01292-17","article-title":"Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats","volume":"61","author":"Schmitt-Hoffmann","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.leukres.2025.108144_bib42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"issue":"5","key":"10.1016\/j.leukres.2025.108144_bib43","article-title":"Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole","volume":"10","author":"Risum","year":"2021","journal-title":"Antibiot. (Basel)"},{"issue":"2","key":"10.1016\/j.leukres.2025.108144_bib44","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14045","article-title":"Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole","volume":"25","author":"Scott","year":"2023","journal-title":"Transpl. Infect. Dis."},{"issue":"9","key":"10.1016\/j.leukres.2025.108144_bib45","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/cid\/ciac230","article-title":"Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies","volume":"75","author":"Rausch","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.leukres.2025.108144_bib46","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients","volume":"70","author":"Fontana","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.leukres.2025.108144_bib47","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/cid\/ciaa358","article-title":"Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study","volume":"72","author":"Bose","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.leukres.2025.108144_bib48","article-title":"Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients","volume":"25","author":"Khatri","year":"2023","journal-title":"Transpl. Infect. Dis."},{"issue":"8","key":"10.1016\/j.leukres.2025.108144_bib49","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/myc.12924","article-title":"Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre","volume":"62","author":"Bowen","year":"2019","journal-title":"Mycoses"},{"issue":"4","key":"10.1016\/j.leukres.2025.108144_bib50","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.04569-14","article-title":"Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study","volume":"59","author":"Cornely","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.leukres.2025.108144_bib51","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bbmt.2020.02.009","article-title":"A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation","volume":"26","author":"Stern","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"10273","key":"10.1016\/j.leukres.2025.108144_bib52","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.leukres.2025.108144_bib53","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/1078155218806975","article-title":"Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome","volume":"25","author":"Phillips","year":"2019","journal-title":"J. Oncol. Pharm. Pr."},{"issue":"5","key":"10.1016\/j.leukres.2025.108144_bib54","first-page":"365","article-title":"Comparison of clinical pharmacology of voriconazole and posaconazole","volume":"20","author":"Sienkiewicz","year":"2016","journal-title":"Conte Oncol. (Pozn. )"},{"key":"10.1016\/j.leukres.2025.108144_bib55","first-page":"1","article-title":"Invasive Aspergillosis and the Impact of Azole-resistance","author":"Bosetti","year":"2023","journal-title":"Curr. Fungal Infect. Rep."},{"key":"10.1016\/j.leukres.2025.108144_bib56","first-page":"2173","article-title":"Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species","volume":"7","author":"Whaley","year":"2016","journal-title":"Front Microbiol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625006344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625006344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T05:22:48Z","timestamp":1767936168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625006344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":56,"alternative-id":["S0145212625006344"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108144","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108144"}}